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Summary: Specific binding-of [3H]oestradiol-17j3 by the cytosol fraction of human renal cell carcinoma was studied.
The binding reaction displayed marked ligand specificity and high affinity of binding. Unlabelled oestradiol, oestriol
and oestrone inhibited the binding of [3H]oestradiol-17|3 to the cytosol binding sites, whereas all other steroids tested
turned out to be only weak or insignificant competitors for the oestrogen binding sites. Scatcliard analyses suggested
the existence of a single class of binding sites. The dissociation constant of the oestradiol-binder complex was found
to be 2.51 ± 0.75 10"9 mol/1. The number of binding sites was limited (17.5 ± 3.8 fmoles per mg of cytosol pro-
tein). Sucrose gradient centrifugation revealed these binding components to be macromolecules, either displaying
a complex sedimentation pattern (peaks at 3.5S, 4S, 5.7S and, in addition, high molecular weight aggregates) or
sedimenting in the 4 S region alone. By agar gel electrophoresis it could be demonstrated that the oestradiol-binding
components migrated into the receptor region of the gel. Binding of [3H]oestradiol-17j3 to these entities was markedly
reduced, when the cytosol was heated (60 min at 45°C) prior to the reaction with the labelled hormone. Since the
specific binding components exhibit properties of oestradiol receptors in target tissues, a direct effect of oestradiol
on human renal cell carcinoma is suggested.
Ostrogefcbindende Komponenten in hypernephroiden Karzinomen des Menschen
Zusammenfassung: Die spezifische Bändung von [3H]Östradiol-17)3 durch die Cytosolfraktion hypernephroider Nieren-
karzinome des Menschen wurde untersucht. Die Bindungsreaktion zeigte eine ausgeprägte Spezifität und hohe Affinität.
Unmarkiertes Östradiol, Östriol und Östron hemmten die Bindung von [3H]Östradiol-17|8, während alle übrigen
getesteten Steroide sich nur als schwache bzw. nicht signifikante Kompetitoren erwiesen. Scatchard-Analysen deuten
auf nur eine Klasse von Bindungsstellen hin. Die Dissoziationskonstante des Östradiol-Binderkomplexes betrug
2,51 ± 0,75 nmol/1. Die Zahl der Btadungsstellen war limitiert (17,5 ± 3,8 fmol/mg Cytosolprotein). Saccharosegradi-
entenzentrifugation zeigte, daß diese Bindungskomponenten Makromoleküle waren. Das Sedimentationsprofil war
entweder komplex (Maxima bei 3,5S, 4S, 5,7S und zusätzlich hochmolekulare Aggregate) oder zeigte nur ein Maxi-
mum in der 4 S=Region. Durch Agarelektrophorese konnte demonstriert werden, daß die östradiolbindenden Kom-
ponenten in die Rezeptorregion des Gels wanderten. Die Bindung des tritiierten Hormons an diese Moleküle nahm
erheblich ab, wenn das Cytosol vor der Reaktion mit dem radioaktiv markierten Östradiol erhitzt wurde (60 min bei
45°C). Da die spezifischen Bindungskomponenten Eigenschaften von Östradiolrezeptoren in Zielorganen haben, wird
eme direkte Wirkung von Östradiol auf hypernephioide Karzinome des Menschen erwartet.
Introduction advanced renal cancer as well as treatment with cytotoxic
drugs have been disappointing (2, 3). In this situation
Between 70 and 80 per cent of all malignant kidney Bloom (4), Samuels (5), Paine (6) and Brühl(l) have
tumours are renal cell carcinomas (1). Even if at the time drawn attention to the possibility of achieving significant
of nephrectomy no distant metastases can be detected, tumour regression in a limited number of patients with
about 50 per cent of the patients die within 5 years after renal carcinoma by administering steroid hormones. The
removal of the primary tumour (1). Radiotherapy of concept of an endocrine dependence of renal cancer in
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man was derived from an oestrogen-induced renal adeno-
carcinoma of the male golden hamster (7, 8). The histo-
logical appearance of this tumour was found to be similar
to that of human carcinoma (9). Anti-oestrogens,
testosterone and progestagens markedly inhibited the
production and growth of these tumours (8, 10, 11).
Furthermore, clear evidence has been accumulated on the
presence of oestrogen receptors in hamster tumours (12,
13). However, caution is necessary when extrapolating
from observations in laboratory animals to clinical
practice (4). Moreover, only a limited number of patients
respond to hormonal therapy. Consequently, it is desir-
able to select those patients who are most likely to
respond. Therefore, information on steroid hormone
receptors in human renal carcinoma may be useful in
supporting the hormonal background of these tumours,
and in the design of a well-controlled therapy for advanced
renal cancer in man. This paper describes the detection of




[2,4,6,7-3HJoestradiol-170 (110 Ci/mmol) and Omnifluor were
obtained from New England Nuclear. All unlabelled hormones
were purchased from Calbiochem. Serva served as a source of
Norit A, while Dextran T 500 was obtained from Pharmacia.
Agar purum and bovine serum albumin were obtained from Beh-
ring, Marburg. All other chemicals were commercial preparations
of analytical grade.
Dextran-Coated Charcoal Assay
This method was based on KorenmarCs procedure (14). Cytosois
(0.2 ml portions), prepared in Tris buffer B, were reacted with
0.2-4.0 nmol/l [3H]oestradiol-170 for 14.hi at 0-3°C, either
alone or in the presence of unlabelled competitive hormones at
1 μηιοΐ/ΐ. Details of individual experimental designs are given in
the legends to figures and tables. Subsequent to the incubation
the samples were combined with 0.5 ml of 5 g/1 Norit A, 50 mg/l
Dextran Τ 500, 10 mmol/1 Tris-HCl, 1 rnmol/1 Na2EDTA, 0.25
mol/l sucrose at ρ Η 8.0. The mixture was incubated at 0—3°C for
5 min and then centrifuged for 2 rnin at 12 000 rev./min in an
Eppendorf centrifuge, model 3200. Portions (0.2 ml) of the
supernatant fluid were pipetted into scintillation vials together
with 10 ml ofBray^s scintillation fluor (15) for counting of
radioactivity.
Sucrose Gradient Centrifugation
The assay procedure closely paralleled the one originally described
by Toft & Gorski (16). Briefly, aliquots (200 μΐ) of cytosol, pre-
pared in Tris buffer A, were reacted with [3H]oestradiol-170 for
2 hr at 0-3°C either alone or in the presence of unlabelled
hormones at 1 μιηοΐ/ΐ. Portions (500 μΐ) of 5 g/1 Norit A,
50 mg/l Dextran 1500,10 mmol/1 Tris-HCl, 1.5 mmol/1 Na2-
EDTA at pH 7.4 were centrifuged for 2 min at 12 000 rev./min in
an Eppendorf centrifuge. The supernatants were discarded. The
labelled cytosols were then mixed with the charcoal pellets and
processed as described under dextran-coated charcoal assay. The
supernatant fluids were assayed for receptor activity by layering
over linear 50-200 g/1 sucrose gradients in Tris buffer A. These
gradients were centrifuged in a Beckman L2-65 B preparative
ultracentrifuge for 16 h at 56 000 rev./min (0 °C) using a
Spinco S W 56 titanium rotor. After centrifugal iori, the bottom
of the tubes were pierced and a 6-drop fraction collected into
scintillation vials containing 2 ml ethanol (99%). Ten ml of
toluene scintillation cocktail (4 g of Omnifluor/1 toluene) were
added to each fraction and the radioactivity measured.
Protein Determination
Protein was estimated by Lo wry 's method (17) using bovine serum
albumin as a standard.
Patients
In 1974 and 1975 six male patients, aged 58 to 79, with a
massive unilateral kidney tumour and no detectable metastases
were nephrectomized at the Urologische Klinik der Universit t
D sseldorf. All patients had neither been subjected to pre-
operative irradiation nor treatment with cytotoxic drugs.
Collection and Handling of Tumour Specimens
Immediately after removal of the primary tumour, specimens
were taken, debribed of necrotic and hemorrhagic areas, and
instantly immersed in liquid nitrogen. Routinely, paraffin sections,
8 to 10 μιη thick, were made from samples of the tissue obtained.
They were stained with hematoxilin and eosin and then examined
microscopically to ensure that the specimens analysed for oestro-
gen-binding components were renal carcinomas.
Preparation of Tumour Cytosols
Solid specimens (3-7 g), which had been stored in liquid nitrogen
prior to use, were placed in ice-cold Tris buffer A (10 mmol/1
Tris-HCl, 1.5 mmol/1 Na2EDTA, pH 7.4) or f ris buffer B
(10 mmol/1 Tris-HCl, 1 mmol/1 Na2EDTA, 0.25 mol/l sucrose,
pH 8.0) and allowed to stand at 3°C until thawed. The samples
were then minced roughly and stirred gently in the same medium
(1:10, w/v) for 10 min to remove contaminating blood. Subse-
quently, the washed tissue was homogenized in a Dual homo-
genizer with cold Tris buffer A or B (1:3, w/v). Finally, the
homogenate was centrifuged at 105 000 g (3°C) for 30 min and
the supernatant (cytosol) carefully removed with a Pasteur
pipette.
Agar Gel Electrophoresis
Electrophoresis closely paralleled that originally described by
Wagner (18). Briefly, tumour specimens (1-2 g) which had
been stored in liquid nitrogen, were pulverized in three
volumes of Tris buffer C (10 mmol/1 Tris-HCl, 1 mmol/1
NaN3, pH 7.5) in a mortar chilled with liquid nitrogen. The
powder was allowed to thaw at 4°C. Subsequently, the thawed
homogenate was centrifuged at 105 000 £ (3°C) for 30 min
in order to prepare the cytosol. Cytosols (0.2 ml portions)
were incubated for 2 hi at 0-3°C with 10 nmol/l I3H)oestra-
diol-170. Non-specific binding of the hormone was determined
in parallel incubations with cytosols, which had been heated
for 1 hr at 45°C. Following the incubation, 50 μΐ portions of
the cytosols were pipetted into each of the 10 sample-wells
punched at the center line of the agar slab. During electro-
phoresis (130 mA* 70 rnin), the temperature in the receptor
region of the gel was continuously monitored by an epoxy-
coated extra small thermistor (Yellow Spring Instrument Co,
part # 44202) and maintained at 3-4°C by cooling of the teflon-
coated braes block. After the run, the individual analyses were
separated by lengthwise slicing the gel slab. The strips were
cut into 5 mm sections with a razor-blade. The samples were
placed into wire-gauze baskets, coated with a thin layer of black
paper. The strips were then dried at 60°C for 12 h. Using sample
holders attached to screw caps (BF-Vertricbs GmbH, Karlsruhe),
the baskets were placed into glass scintillation counting vials,
containing 0.5 ml distilled water. With the aid of a simple
device up to 40 vials were evacuated and filled with oxygen
(19). The screw caps were then sealed gas tight and automatic
uv-vial combustion started, using the Micro-Mat BF 5010 (BF-
Vertriebs GmbH, Karlsruhe). This procedure is a modification
of the technique originally described by Gupta (20). When
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combustion of the samples was complete, the vials were allowed
to stand at - 10°C for about 5 min in order to completely
condense the tritium water-vapor. Subsequently, the special
sample holders were removed, 10 ml of Bray's scintillation fluor
(15) added to each vial, and the samples were ready for liquid
scintillation counting.
Results
For determination of the nature of the molecular species
binding oestrogen, cytosols prepared from human renal
cell carcinoma were reacted in vitro with [3H]oestradiol-
170 and then analyzed by the dextran-coated charcoal
procedure, sucrose density gradient centrifugation, and
agar gel electrophoresis.
Use of the Dextran-Coated Charcoal Assay
The charcoal adsorption assay was used to estimate the
affinity of the binding components for 17j3-oestradiol,
and to ascertain the relative affinities of other steroid
hormones for the oestradiol-binding entities.
Titration of the cytosol
The affinity of oestradiol binding to cytoplasmic compo-
nents of renal cell carcinoma was determined by in-
cubating the cytosol with increasing concentrations of
[3H]oestradiol-17j3. At each concentration the specific
binding was determined by subtracting the amount of
tritiated hormone complexed non-specifically in an
identical reaction, containing the same concentration of
[3H]oestradiol-17|3 but in addition unlabelled oestradiol
at 1 μπιοΐ/ΐ. Saturation type binding curves were obtained
(not shown). To estimate the dissociation constant of the
oestradiol-binder complex and the maximal number of
binding sites, the results were analyzed by the Scatc/iard
method (21). As can be seen in Figure 1, a plot of the
concentration of oestradiol bound versus the ratio of
bound over free oestradiol closely approximates to a
straight line. From the slopes ofScatchard plots over the
indicated range of hormone concentrations the disso-
ciation constants for the reaction: oestradiol + binder
^—oestradiol-binder complex was calculated and found
to be 2.51 ± 0.75 X 10~9 mol/1 (mean ± SEM of four
individual experiments). Assuming that the binding
entities are univalent arid that only a single class of
specific binding components exists under the conditions
of the assay, the maximal concentration of the binding
entities was determined to be 17.5 ± 3.8 fmoles per mg
of cytosol protein (mean ± SEM of four individual
experiments), ranging from 10 to 27 fmoles per mg
of protein.
Ligaivl specificity
The relative affinities of various steroids for the
17)3-oestradiol binding components, as measured by
0 50 100
Oestradiol -17/3, bound [pmol/l]
Fig. 1. Scatchard analysis of the titration data for the oestrogen-
binding components in the cytosol of human renal cell
carcinoma. 105 000 £ supernatants (0.2 ml portions),
prepared in Tris buffer B, were reacted with increasing
concentrations of [3HJoestradiol-170 (0.2-3.7 nmol/1)
at 0-3°C for 14 h either alone or in the presence of
unlabelled 170-oestradioi at 1 μπιοΐ/ΐ. Binding was
measured by the dextran-coated charcoal assay.
K D = 1.3 X 10·* moJ/1.
competition studies, are summarized in Table 1. The
ligand specificity for binding to these entities indicated
a requirement for oestrogens. These results are similar
to those reported for normal human kidney (22). Pro-
gesterone turned out to be a moderate competitor for
oestrogen binding sites. Weak inhibition of oestradiol
binding was observed in the presence of cortexolone,
while aldosterone, corticosterone, cortisol and dihydro-
testosterone seem to compete only insignificantly with
oestradiol for binding to these sites.
Tab. 1. Ligand specificity of [3H)oestradiol-170 binding by cyto-
sol from human renal cell carcinoma. Cytosols (0.2 ml
portions), prepared in Tris buffer B, were incubated with
4 nmol/1 [^HJoestradiol-n/!? for 14 h at 0-3°C, either
alone or in the presence of a competitive substance at
1 jumol/1. Each reaction was terminated by the addition
of 0.5 ml of the dextran-coated charcoal reagent. Inhi-
bition of specific [3HJoestradiol-17/3-binding is expressed
as percentage of control value.
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Sucrose Gradient Centrifugation
Isotopic profiles of the cytoplasniic oestradiol binding
components separated on low ionic strength sucrose
density gradients (50-200 g/1), are shown in Figure 2.
Specific binding is indicated by the difference in the
areas under the peaks, obtained in the absence (closed
circles) or presence (open circles) of an excess of un-
labelled 17/3-oestradiol. Analysing the cytosols from
different renal cell carcinomas, two distinct types of
isotopic profiles were obtained. In both plots (Fig. 2,
profile A and profile B) specific binding of 170-oestradiol
to macromolecular species, sedimenting in the 4.2—4.4S
region of the gradient, can be seen. In profile A (Fig. 2),
however, additional specific binding components at
about 3.5S and 5.7S are discernible. Moreover, a signi-
ficant fraction of the radioactivity was recovered at the
bottom of the tube, thus, exhibiting a high sedimentation











Fig. 2. Representative isotopic profiles of oestrogen-binding
macromolecules, separated by sucrose gradient centrifuga-
tion of cytosols, obtained from human renal cell carci-
noma. Aliquots (0.2 ml) of cytosol, prepared in Tris buffer
A, were incubated with 3 nmol/1 [3H]oestradiol-170for
2 h at 0-3°C either alone (closed circles) or in the presence
of unlabelled oestradiol at 1 μιηοΐ/ΐ (open circles). The
cytosols were subjected to dextran-eoated charcoal treat-
ment and then assayed for binding activity by layering
over linear 50-200 g/1 sucrose gradients in Tris buffer A.
The gradients were centrifuged for 16 h at 56 000 rev./min
(0°C) using a Spinco SW 56 titanium rotor.
17j3-oestradiol forms a complex with cytosol macromole-
cules which tends to aggregate. All peaks represent satur-
able steroid binding sites, for binding is inhibited by an
excess of unlabelled oestradiol.
Agar Gel Electrophoresis
For further characterisation of the oestrogen binding
components in human renal cell carcinoma, the cytosol was
submitted to agar gel electrophoresis at low temperature
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Fig. 3. Electrophoretic separation of cytoplasmic oestrogen-
binding components from human renal cell carcinoma.
Cytosols were reacted with 10 nmol/1 |3H]oestradioi-170
for 2 h at 0-3°C (Profile A). The heat lability of the
binding components was determined in parallel incubations
with cytosol, which had been heated for l h at 45°C
(Profile B). Aliquots (50 μΐ) of the cytosols were then
• separated by agar gel electrophoresis (10 g/1,agar gel,
130 mA,,70 min, 3-4°Cgel temperature). 5 mm sections
were counted after in vial combustion.
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and sex-hormone-binding globulin which may be present
in human tissue extracts due to serum contamination
(18). Receptor proteins migrate towards the anode,
whereas sex-hormone-binding globulin and free oestradiol
move towards the cathode. Moreover, high affinity
binding to receptor sites can be distinguished from low
affinity binding to serum contaminants, the oestradiol
complexes of which do not withstand agar gel electro-
phoresis. As can be seen in profile A (Fig. 3), high affinity
binding of [3H]oestradiol-17|3 could be clearly demon-
strated in the receptor region of the gel. In profile B
(Fig. 3), the heat lability of these binding components
is shown. In this experiment, the cytosol was heated for
60 min at 45°C prior to the reaction with the tritiated
hormone. It can be clearly seen that the majority of the
binding entities in the receptor region displayed a heat
lability, which closely resembles that of oestrogen
receptors in target tissues (23).
Discussion
The results presented here demonstrate the existence of
oestradiol binding components in the cytoplasmic fraction
of human renal cell carcinoma. The ligand specificity for
binding to these components compares well with that of
normal rat (24) and human kidney (22). The fact that
a large excess of unlabelled aldosterone did only weakly
compete with tritiated 17/3-oestradiol for binding to these
entities, suggests that the oestradiol-binding sites are in-
dependent of mineralocorticoid receptors. The inability
of dihydrotestosterone to compete with oestradiol for
binding to these components clearly excludes a "cross-
affinity" of 17/J-oestradiol for an androgen receptor,
which may be present in renal cell carcinomas of male
patients. Interestingly, progesterone, which is known to
cause a significant tumour regression in a limited number
of patients with renal cell carcinoma (4, 5, 6) turned out
to be a moderate competitor of [3H]oestradiol-17j3 binding
to these components. By agar gel electrophoresis it could
be demonstrated, that the oestradiol-binding entities
exhibited an electrophoretic mobility, which was different
from that of sex-hormone-binding globulin and which
closely resembles that of oestrogen receptors in target
tissue (18, 23). The heat lability of the binding compo-
nents provides further presumptive evidence for these
binding sites being oestrogen receptors (23). The binding
reaction displayed saturation kinetics and high affinity
binding of the hormone to cytosol macromolecules.
The dissociation constant of the binder-ligand complex
from the cytoplasmic fraction of human renal cell car-
cinoma (2,51 ± 0.75 X 10~9 mol/1) is strikingly similar
to that of normal human kidney (2.2 ±0.1 X 10"9 mol/1),
R 3230 AC rodent mammary adenocarcinoma (1.2 10"9
mol/1), and human breast carcinoma (0.9 10"9 mol/1)
(22, 25, 26). The binding capacity of the cytosol of
human renal cell carcinoma was found to be 17.5 ± 3.8
fmoles per mg of cytosol protein. In comparison to this
value, the oestradiol receptors in normal human kidney
cytosol (22) appear to be of higher capacity (34.0 ± 9.7
fmoles/mg protein). Similar to human breast carcinoma
(26), the oestrogen binding capacity of cytosol prepared
from different tumour specimens varied considerably
(10-27 fmoles/mg protein). It seems reasonable to
assume, that the variability of the number of binding
sites reflects interindividual differences in the receptor
content. Moreover, it is most likely, that the oestrogen-
binding components are not evenly distributed among
the tumour tissue. These intraindividual variations in
receptor content may be due to the obvious hetero-
geneity of the tumour cell population. The sedimentation
patterns of the oestradiol-binding entities on sucrose
density gradients display interindividual and/or intra-
individual variations. However, in both profiles
(Fig. 2, profile A and B) sedimentation of the binder-
ligand complex at about 4S can be seen. This sedimen-
tation behaviour is very similar to that of inactivated
receptor complexes in various target organs. It remains
to be elucidated whether the peak at 3.5 S (Fig. 2, pro-
file A) indicates specific binding to biosynthetic pre-
cursors of the oestradiol receptors (P. W. Jungbluth,
pers. communication). Although, further studies are
required, to shed light on the nature of the 5.5-5.8 S
peak (Fig. 2, profile A), it is tempting to suppose that
this peak represents binding of the hormone to the
active receptor dimer, sedimenting in the 5 S region
(P. W. Jungbluth, pers. communication, (27)). The
finding of oestradiol-binding components, which display
characteristics of oestrogen receptors in target organs,
raises a number of intriguing questions. Is the presence
of such a binding component in human renal cell carci-
noma merely incidental? If this is not so, what is the
function and significance of such receptor sites in tumour
cell metabolism? Do all renal cell carcinomas contain
oestradiol receptors? Is the occurrence of receptor
molecules restricted to a subpopulation of tumour
cells? Experiments to determine the exact cellular
source in human renal cell carcinoma for the oestrogen-
binding components are in progress.
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